Parasitic protozoa from the genus Leishmania are the causative agents for the variety of clinical manifestations of leishmaniasis, a disease with an annual incidence of 2 million people worldwide according to the World Health Organization (http://www.who.int/emc/diseases/leish/leisdisl.html). Treatment currently relies exclusively on chemotherapy. The development of both new drugs and fast low-cost tests for their screening are required due to the growing incidence of drug resistance against both first-line and alternative drugs (12), together with their frequent severe side effects.
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When compared with drug screens available for most microorganisms, Leishmania proliferation assays are frequently time-consuming procedures; hence, definitions of other vital parameters to speed up this process are needed.
ATP levels define the energetic state of Leishmania spp. Oxidative phosphorylation is essential to fulfill the minimal energetic requirements of the parasite (1, 22) . Hence, drugs affecting mitochondrial ATP production, such as licochalcones or naphthoquinones, are potentially good leishmanicidal candidates (6, 7, 25) . A decrease of the intracellular ATP is induced by these drugs since glycolysis is unable to fully counterbalance this decrease.
Nevertheless, ATP measurement by the standard luciferinluciferase luminescence assay (9) is a time-and material-consuming method, which is also difficult to automate. Techniques such as nuclear magnetic resonance, also enable an examination of ATP variation in vivo, but a high number of cells and sophisticated equipment is required.
As an alternative approach, we have optimized a fast and easy luminescent method involving a technique to bypass the poor permeability of D-luciferin at neutral pH (5, 24) by the use of D-luciferin-[1-(4,5-dimethoxy-2-nitrophenyl) ethyl ester] (DMNPE-luciferin), a caged membrane-permeable luciferin ester, and promastigotes transfected with a firefly luciferase gene mutated in its C-terminal tripeptide sequence, disabling its intracellular transport into the glycosomes (21) and retaining the enzyme inside the cytoplasm. In order to validate the system, the inhibition of luminescence by a set of drugs affecting mitochondrial physiology was compared with their effects on mitochondrial membrane potential and promastigote proliferation.
MATERIALS AND METHODS
Construction of the expression vector pX63NEO-3Luc. Phothinus pyralis luciferase gene (luc) with a mutation in the last three amino acids was a kind gift from T. Aesbicher and I. Vorberg (Max Planck Institut für Biologie, Tübingen, Germany) (21) . The luciferase gene was inserted at the BamHI restriction site of the polylinker of the Leishmania expression vector pX63NEO (17) . Insert orientation was checked by electrophoretic analysis of the resulting fragments after digestion with BglII and Asp718. The plasmid was purified using QIAprep Spin Miniprep kit (Qiagen, Hilden, Germany), and its purity was assessed by agarose electrophoresis.
Parasites. Leishmania donovani promastigotes (MHOM/SD/00/1S-2D), kindly provided by S. Turco, Kentucky University, were transfected with pX63NEO-3Luc containing the luciferase mutated gene, either in the right (3-Luc strain) or the reversed (Neo strain) orientation by electroporation, according to the method of Lebowitz (16) . Parasites were selected by growth in RPMI 1640 medium (Gibco, Paisley, United Kingdom) supplemented with 10% heat-inactivated fetal calf serum, 24 mM NaHCO 3 , 25 mM HEPES, 2 mM D-glutamine, 100 U of uniciline per ml, 48 mg of gentamicin per ml, and 30 g of geneticin (G-418; Gibco) per ml (RPMI-HIFCS) at pH 7.2, a medium which was also used for parasite maintenance.
Promastigotes were harvested at late exponential phase and washed twice in Hanks buffer supplemented with 10 mM D-glucose (pH 7.2) at 4°C (Hanks-Glc).
Drugs. A total of 14 drugs, summarized in Table 1 , were tested. Buparvaquone, plumbagin, and lawsone, all naphthoquinone derivatives were used as positive controls (6, 7, 19) , while the other compounds were tested blind. Drug concentrations are stated in the corresponding tables and figures. Controls used the same amount of the corresponding solvent.
Estimation of luciferase expression levels in transfected Leishmania promastigotes. The Luciferase Assay System Kit (Promega, Madison, Wis.) was used according to the directions of the supplier. Luminescence was measured in an LKB Bio-Orbit 1250 luminometer at 1 and at 3 min after mixing. The optimal range of parasites was 10 5 promastigotes per assay. Luminescence from lysates was compared with a standard purified P. pyralis luciferase (Roche Molecular Biochemicals, Barcelona, Spain) mixed with the same amount of cell lysate from the Neo strain.
Setup of standard bioluminescence assay. Stock solutions (5 mM) of both D-luciferin and its caged analogue DMNPE-luciferin (Molecular Probes, Leiden, The Netherlands) were made in dimethyl sulfoxide. The substrate was added to a promastigote suspension (2 ϫ 10 7 cells/ml) in Hanks-Glc at a final concentration of 25 M (final volume, 200 l). After mixing, luminescence was monitored in an LKB Bio-Orbit 1250 luminometer, averaging the luminescence values every 10 s. Drugs were added when luminescence reached a plateau; this point was considered time zero, and its luminescence level was taken as 100%. In a set of initial experiments, metabolic inhibition of parasites by 2 mM KCN and/or 10 mM 2-D-deoxyglucose (2-dGlc) was carried out following of promastigotes for 4 h in Hanks solution plus 2 mM D-Glc.
Oxygen consumption rates. Oxygen consumption rates were measured in a Clarke oxygen electrode (Hansatech, KingsLynn, United Kingdom) at 25°C as described earlier (9) using 0.8 ml of a parasite suspension (10 8 cells/ml). Evaluation of ⌬⌿ m . The change in mitochondrial membrane potential (⌬⌿ m ) in intact promastigotes was estimated by measuring rhodamine-123 (Molecular Probes) accumulation (9) . Parasites (2 ϫ 10 6 promastigotes/ml) were resuspended in Hanks-Glc and incubated with the different drugs for 30 min at 25°C. After that, parasites were loaded with rhodamine-123 (0.3 g/ml, 5 min, 37°C), washed by centrifugation, and resuspended in Hanks-Glc at a final density of 10 6 cells/ml. Drug accumulation was tested immediately in a Coulter XL EPICS cytofluorometer (excitation and emission wavelengths of 488 and 525 nm, respectively). Depolarized parasites, incubated with 7.5 M carbonyl cyanide ptrifluoromethoxyphenylhydrazone (FCCP) or 2 mM KCN were considered as negative controls.
Cell proliferation measurements. Parasites were resuspended in growth medium (RPMI-HIFCS) devoid of phenol red at a final density of 2 ϫ 10 6 promastigotes/ml, divided into aliquots, placed in a 96-well culture microplate (100 l/well), and incubated with drugs for 48 h at 25°C. After that, an equal volume of (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (MTT) solution (1 mg/ml) in Hanks-Glc was added to each well, and the wells were incubated for 2 h at 25°C. Precipitated formazan was solubilized by the addition of 100 l of 10% (wt/vol) sodium dodecyl sulfate solution and read in a 450 Bio-Rad microplate reader equipped with a 600-nm filter. For those drugs affecting MTT reduction, proliferation was measured by cell counting in a Neubauer chamber. Only full motile promastigotes were considered viable (9). 
RESULTS
Optimization of the bioluminescence assay. The levels of luciferase in transfected promastigotes were estimated by enzymatic activity as (2.52 Ϯ 0.27) ϫ 10 3 copies/promastigote. This value is 10 times higher than that obtained for the native glycosomal form of the enzyme (data not shown).
Both free D-luciferin and its neutral ester (DMNPE-luciferin) were compared as luminescence substrates (Fig. 1) . Upon addition of the substrate, the luminescence increased rapidly and dependent on substrate concentration between 2.5 and 25 M. At 25 M the luminescence obtained with DMNPEluciferin was approximately four times higher than that with D-luciferin (Fig. 1) . The maximum level was reached ca. 10 min after DMNPE-luciferin addition, followed by slow decay for at least 1 h.
When assayed at 25 M DMNPE-luciferin, luminescence was directly proportional to the cell number (Fig. 1, inset) . Luciferase activity depleted total ATP content by only 3.8% Ϯ 1.5% from its initial value of 15 nmol/mg of protein (1 mg of protein ϭ 3.6 ϫ 10 8 promastigotes). Treatment of parasites with 10 mM 2-dGlc (a competitive inhibitor of glycolysis) or with 2 mM KCN (as inhibitor of the respiratory chain) led to luminescence decreases of 22 and 85%, respectively, and to a decrease of 97% when these inhibitors were added together. Effects of naphthoquinones on promastigote bioluminescence and other viability parameters. To remove false negatives caused by a direct inhibition of luciferase, drugs were tested in vitro at their highest concentration on purified luciferase. None of the drugs produced a significant in vitro inhibition (Ͼ5%).
Buparvaquone and plumbagin inhibited parasite luminescence in vivo at nanomolar and micromolar concentrations (Table 1) but not the natural hydroxynaphthoquinone lawsone, reported previously as inactive (1, 19) .
A good correlation was obtained for the ED 50 of buparvaquone (an inhibitor of respiratory chain) and plumbagin (uncoupler of oxidative phosphorylation) for parasite proliferation, ⌬⌿ m , and luminescence (Table 1) . Lawsone was inactive in the three systems (ED 50 Ͼ50 M) ( Table 1) .
Validation of the luminescence test with other drugs. A set of 14 drugs was assayed blind in the luminescence assay using an initial cutoff of 50 M. In these tests only six compounds inhibited luminescence (Fig. 2) . Plumbagin, 1-4 naphthoquinone, pyronaridine, and menadione were active as inhibitors of luminescence at a micromolar concentration, whereas buparvaquone and juglone were active at a nanomolar concentration range. As above, a good correlation between luminescence decrease with the other two parameters was obtained (Table  1) .
When the same set of drugs was tested for inhibition of promastigote proliferation, another two drugs (mepacrine and pentamidine), inactive at 50 M by the standard luminescence test, were highly inhibitory (Table 1) . Nevertheless, either when the pentamidine concentration was increased to 100 M or when the parasites were preincubated with 50 M mepacrine for 4 h prior to DMNPE-luciferin addition, the luminescence levels were decreased to 25.5% Ϯ 7.8% and 28.2% Ϯ 4.3%, respectively, compared to the control parasites. This result suggested a slow accumulation of mepacrine, confirmed by the decrease in the oxygen consumption rates of parasites permeabilized with digitonin, making mitochondria accessible to the drug. The control rate for intact parasites (8.45 nmol O 2 ϫ min Ϫ1 ϫ [10 8 cells] Ϫ1 ) was not modified at 10 M mepacrine, whereas in permeabilized parasites a decrease of 26.5% was observed at this concentration.
DISCUSSION
Microorganisms transfected with P. pyralis luciferase have been extensively used to improve proliferation assays in slowdividing organisms, such as Mycobacterium tuberculosis (13, 20, 33) . However, the potential of using the internal expression of luciferase as a probe to monitor in vivo changes in metabolism affecting intracellular ATP levels have not been fully explored in higher eukaryotes (15) or parasitic protozoa. This is due to the substrate limitation caused by the poor membrane permeability of D-luciferin at neutral pH and sequestration of luciferase into peroxisomes. We have improved the system and applied it to screen leishmanicidal drugs in a fast-and cost-effective manner by using a free-membrane permeable neutral caged luciferin ester, hydrolyzed once inside the cytoplasm (5, 24) , and parasites transfected with a mutated version of the P. pyralis luciferase gene that retained the enzyme in the cytoplasm (21), with a much better yield in luminescence than the native glycosomal form of the enzyme. Luminescence output is proportional to both the luciferase substrate concentration and the cell number. According to our measurements of total ATP levels, the slow decay observed after the maximum is not produced by ATP depletion by the luminescence reaction but is more likely caused by luciferase inhibition by the end products of D-luciferin (8) .
The standard protocol is biased toward the identification of drugs affecting mitochondrial ATP production rather than inhibitors of glycolysis. This is in agreement with our results on luminescence inhibition by KCN and 2-dGlc, with the correlation between the ED 50 for luminescence and ⌬⌿ m , and with previous reports in the literature (1, 22) , where minimal energetic requirements can only be fulfilled by oxidative phosphorylation and not by glycolysis. Putative inhibitors of the last pathway would be identified indirectly through the depletion of pyruvate, provided that D-glucose was the sole source of carbon and that all the other metabolic intermediates from glycolysis or the Krebs cycle or the internal carbohydrate reservoirs have undergone a strong depletion.
Inhibition of luminescence correlated well (␣ ϭ 0.01) with the leishmanicidal activity of naphthoquinones and hydroxynaphthoquinones (6, 7, 14, 19) . Atovaquone and meglumine antimoniate were not detected since they mainly affect the amastigote stage (7, 17) . In general, the inhibition of proliferation was always higher than the inhibition of luminescence at the same drug concentration. A likely explanation for this is that the loss of parasite viability will require a significant but not total depletion of ATP levels, as seen in similar experiments with rat hepatocytes (15) .
The luminescence assay failed to detect two known leishmanicidal drugs, pentamidine and mepacrine. Mepacrine was described as an inhibitor of topoisomerase II and protein synthesis (11) rather than as a fast effector on the energetic metabolism of the parasite. Even so, luminescence is affected after longer incubation with mepacrine, possibly by an indirect pathway. Pentamidine was reported as an inhibitor of polyamine biosynthesis and kDNA replication (2); however, it also inhibits oxidative phosphorylation on Leishmania promastigotes in digitonin-permeabilized parasites at 200 M (23), a concentration four times higher than our 50 M cutoff. In fact, 100 M pentamidine inhibited luminescence in agreement with this earlier study.
The assay can also uncover effects on bioenergetic metabolism as a putative secondary target for drugs. Pyronaridine, reported to be a DNA polymerase II inhibitor in Plasmodium falciparum (4) , produced a considerable inhibition of luminescence, and a possible inhibition on luciferase was excluded by in vitro assays on parasite lysates. This is also confirmed by the good correlation obtained in our assay with bioenergetic parameters directly related to ATP production in mitochondria, such as the membrane potential ⌬⌿ m .
An intrinsic limitation of the method is its restriction to the promastigote, the only stage where the expression of genes inserted into the pX63NEO vector reached good levels (17) . Since new expression vectors for amastigotes are being improved (3), this strategy should be explored further. However, assays in infected macrophages will be limited by the access of D-luciferin into the parasitophorus vacuole. The system has advantages over other methods since it requires a lower number of cells than that required for measuring oxygen consumption rate and since it is less time-consuming than measurement of the ⌬⌿ m . This assay is also simple and easy to automate. Although initially designed for fast-acting drugs affecting ATP production, its utility can be extended to the slow-accumulating drugs, as previously discussed, and for other compounds that cause the reduction of ATP levels, such as membraneactive molecules.
